Logo image
Analysis of GP73 in patients with HCC as a function of anti-cancer treatment
Journal article   Open access   Peer reviewed

Analysis of GP73 in patients with HCC as a function of anti-cancer treatment

Hie-Won Hann, Mengjun Wang, Julie Hafner, Ronald E Long, Su Hee Kim, Meejin Ahn, Susan Park, Mary Ann Comunale, Timothy M Block and Anand Mehta
Cancer biomarkers : section A of Disease markers, v 7(6), pp 269-273
01 Jan 2010
PMID: 21694465
url
https://doi.org/10.3233/CBM-2010-0190View
Published, Version of Record (VoR) Open

Abstract

In this study, we examined the level of Golgi protein 73 (GP73) in the serum of 9 patients as a function of anti-liver cancer treatment. Although the numbers are small, a clear trend was observed. Patients who remained tumor free (up to 6 years post-treatment) showed reductions in GP73 at the first time point available post-treatment. In contrast, patients who had high levels GP73 post treatment all had re-occurrence within a 5 year period. These data are preliminary but dramatically imply that this marker may have value in the monitoring of HCC patients and may be elevated even when small, undetectable tumors are present.

Metrics

15 Record Views
20 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Oncology
Logo image